Consensus development conference: prophylaxis and treatment of osteoporosis.Am J Med1993; 94: 646–50.
2.
ParfittA.M.Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis.Miner Electrolyte Metab1980; 4: 273–87.
3.
KanisJ.A.Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group.Osteoporos Int1994; 4: 368–81.
SilverbergS.J., ShaneE., JacobsT P., SirisE., BilezikianJ P.A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.N Engl J Med1999; 341: 1249–55.
6.
ParisienM., CosmanF., MellishR.W.E., SchnitzerM., NievesJ., SilverbergS.J.Bone structure in post-menopausal hyperparathyroid, osteoporotic, and normal women.J Bone Miner Res1995; 10: 1393–9.
7.
DempsterD.W., ParisienM., SilverbergS.J., LiangX.G., SchnitzerM., ShenV.On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism.J Clin Endocrinol Metab1999; 84: 1562–5.
8.
ChristiansenP., SteinicheT., BrixenK., HessovI., MelsenF., HeickendorffL.Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy.Bone1999; 25: 237–44.
9.
KhoslaS., MeltonLJ3rd, WermersR.A., CrowsonC.S., O'FallonW.M., RiggsB.L.Primary hyperparathyroidism and the risk of fracture: a population-based study.J Bone Miner Res1999; 14: 1700–7.
10.
EttingerB., BlackD.M., MitlakB.H., KnickerbockerR.K., NickelsenT., GenantH.K.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial.JAMA1999; 282: 637–45.
11.
ChestnutCH3rd, SilvermanS., AndrianoK., GenantH., GimonaA., HarrisS.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study.Am J Med2000; 109: 267–76.
12.
BlackD.M., CummingsS.R., KarpfD.B., CauleyJ.A., ThompsonD.E., NevittM.C.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.Lancet1996; 348: 1535–41.
13.
CummingsS.R., BlackD.M., ThompsonD.E., ApplegateW.B., Barrett–ConnorE., MuslinerT.A.Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures.JAMA1998; 280: 2077–82.
14.
HarrisS.T., WattsN.B., GenantH.K., McKeeverC.D., HangartnerT., KellerM.Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postemopausal osteoporosis.JAMA1999; 282(14): 1344–52.
15.
ReginsterJ.Y., MinneH.W., SorensonO.H., HooperM., RouxC., BrandiM.L.Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.Osteoporos Int2000; 11: 83–91.
16.
McClungM.R., GeusensP., MillerP.D., ZippelH., BensenW.G., RouxC.Effect of risedronate on hip fracture risk in elderly women.N Engl J Med2001; 344: 333–40.
17.
LindsayR., SilvermanS.L., CooperC., HanleyD.A., BartonI., BroyS.B.Risk of new vertebral fractures in the year following a fracture.JAMA2001; 285: 320–3.
18.
KlotzbuecherC.M., RossP.D., LandsmanP.B., AbbottTA3rd, BergerM.Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis.J Bone Miner Res2000; 15: 721–39.
19.
NeerR.M., ArnaudC.D., ZanchettaJ.R., PrinceR., GaichG.A., ReginsterJ.Y.Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis.N Engl J Med2001; 344: 1434–41.
20.
HodsmanA.B., KisielM., AdachiJ.D., FraherL.J., WatsonP.H.Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis.Bone2000; 27: 311–18.
21.
ChavassieuxP.M., ArlotM.E., RedaC., WeiL., YatesA.J., MeunierP.J.Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.J Clin Invest1997; 100: 1475–80.
22.
BoivinG.Y., ChavassieuxP.M., SantoraA.C., YatesJ., MeunierP.J.Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.Bone2000; 27: 687–94.
23.
DempsterD., CosmanF., KurlandE., ZhouH., NievesJ., WoelfertL.Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.J Bone Miner Res2001; 16: 1846–53.
24.
LindbergJ.S., MoeS.M.Osteoporosis in end-stage renal disease.Semin Nephrol1999; 19: 115–22.
25.
FontaineM.A., AlbertA., DuboisB., Saint-RemyA., RoriveG.Fracture and bone mineral density in hemodialysis patients.Clin Nephrol2000; 54: 218–26.
26.
PirainoB., ChenT., CoopersteinL., SegreG., PuschettJ.Fractures and vertebral bone mineral density in patients with renal osteodystrophy.Clin Nephrol1988; 30: 57–62.
27.
YamaguchiT., KannoE., TsubotaJ., ShiomiT., NakaiM., HattoriS.Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures.Bone1996; 19: 549–55.
28.
Stehman–BreenC.O., SherrardD.J., AllemA.M., GillenD.L., HeckbertS.R., WongC.S.Risk factors for hip fracture among patients with end-stage renal disease.Kidney Int2000; 58: 2200–5.
29.
SherrardD.J., HerczG., PeiY., MaloneyN.A., GreenwoodC., ManuelA.The spectrum of bone disease in end-stage renal failure—an evolving disorder.Kidney Int1993; 43: 436–42.
30.
HerczG., PeiY., GreenwoodC., ManuelA., SaiphooC., GoodmanW.G.Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function.Kidney Int1993; 44: 860–6.
31.
GabayC., RuedinP., SlosmanD., BonjourJ.P., LeskiM., RizzoliR.Bone mineral density in patients with end-stage renal failure.Am J Nephrol1993; 13: 115–23.
32.
WeisingerJ.R., GonzalezL., AlvarezH., HernandezE., CarliniR.G., CaprilesF.Role of persistent amenorrhea in bone mineral metabolism of young hemodialyzed women.Kidney Int2000; 58: 331–5.
Matuszkiewicz–RowinskaJ., SkorzewskaK., RadowickiS., SokalskiA., PrzedlackiJ., NiemczykS.The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis.Nephrol Dial Transplant1999; 14: 1238–43.
35.
QuarlesL.D., LobaughB., MurphyG.Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.J Clin Endocrinol Metab1992; 75: 145–50.
36.
GaoP., ScheibelS., D'AmourP., JohnM.R., RaoS.D., Schmidt–GaykH.Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1–84: implications for improvement of accurate assessment of parathyroid function.J Bone Miner Res2001; 16: 605–14.
37.
MartinK.J., GonzalesE.A., GellensM., HammL.L., AbboudH., LindbergJ.19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.J Am Soc Nephrol1998; 9: 1427–32.
38.
KurokawaK., AkizawaT., SuzukiM., AkibaT., OgataE., SlatopolskyE.Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.Nephrol Dial Transplant1996; 11(Suppl 3): 121–4.
ThiebaudD., BurckhardtP., MelchiorJ., EckertP., JacquetA.F., SchnyderP.Two years’ effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.Osteoporos Int1994; 4: 76–83.
41.
ParfittA.M.Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland.Miner Electrolyte Metab1982; 8: 92–112.
42.
JulianB.A., LaskowD.A., DubovskyJ., CurtisJ.J., QuarlesL.D.Rapid loss of vertebral mineral density after renal transplantation.N Engl J Med1991; 325: 544–50.
43.
GrotzW.H., MundingerF.A., RasenackJ., SpeidelL., OlschewskiM., ExnerV.M.Bone loss after kidney transplantation: a longitudinal study in 115 graft recipients.Nephrol Dial Transplant1995; 10: 2096–100.
44.
Monier–FaugereM.C., MawadH., QiQ., FriedlerR.M., MallucheH.H.High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation.J Am Soc Nephrol2000; 11: 1093–9.
45.
GrotzW.H., MundingerF.A., GugelB., ExnerV.M., KirsteG., SchollmeyerP.J.Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients.Transplantation1994; 58: 912–15.
46.
NisbethU., LindhE., LjunghallS., BackmanU., FellströmB.Increased fracture rate in diabetes mellitus and females after renal transplantation.Transplantation1999; 67: 1218–22.
47.
D'AngeloA., CaloL., GianniniS., CarraroG., BonfanteL., FavaroS.Parathyroid hormone and bone metabolism in kidney-transplanted patients.Clin Nephrol2000; 53: 19–22.
48.
FanS.L.S., AlmondM.K., BallE., EvansK., CunninghamJ.Pamidronate therapy as prevention of bone loss following renal transplantation.Kidney Int2000; 57: 684–90.
